@article{94676,
  author = {Shrestha S and Chaudhary S and Giri H and Marahatta S},
  title = {Dapsone-induced optic atrophy: a rare case report},
  abstract = {Dapsone-induced optic atrophy (OA) is very rare at therapeutic doses. A 43-year-old gentleman on WHO-recommended multibacillary Multi-Drug Therapy (WHO MB-MDT) containing rifampicin, dapsone, and clofazimine, presented with bilateral gradual painless diminution of vision after 3 months of medication. He denied any history of trauma, headache, limb weakness, ataxia, diplopia, temporal pain , or weight loss. There was no history of sudden diminution of vision in family members. Fundus examination showed bilateral pale optic discs with well-defined margins. Glucose-6-phosphate dehydrogenase (G6PD) was normal. He was diagnosed with OA secondary to dapsone. There is therefore a possibility of dapsone induced OA even at the therapeutic dose. Hence, we should perform routine eye check-up before starting dapsone.},
  year = {2020},
  journal = {Leprosy Review},
  volume = {91},
  pages = {291-294},
  publisher = {Lepra},
  issn = {2162-8807},
  url = {https://leprosyreview.org/article/91/3/20-20020},
  doi = {10.47276/lr.91.3.291},
  language = {eng},
}